Source: http://health.yahoo.net/news/s/nm/actavis-ceo-originators-to-have-edge-in-biosimilars
Monday, 22 October 2012
Actavis CEO: originators to have edge in "biosimilars"
FRANKFURT (Reuters) - The market for cheap copies of biotech drugs could initially be dominated by the very companies that develop these drugs, rather than established generic drug makers, the outgoing head of Switzerland's Actavis said. The m...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: only a member of this blog may post a comment.